AnorMED has announced today the enrollment of HIV patients into its new clinical trial to evaluate the potential of AMD070 as a new anti-HIV drug.
The XACT (X4 Antagonist Concept Trial) trial is being conducted at two leading HIV research centers, one in the U.S. and one in the UK. XACT is an open-label, dose-finding study which may include up to four study cohorts of 12 patients each. Patients in the first cohort will receive 200 mg of AMD070, twice daily, for 10 consecutive days. The objective of the study is to determine the safety and antiviral activity of AMD070 in HIV-infected patients who harbor the CXCR4 using virus. Initial data from this study is expected in early 2006.